StockMacro
Menu

Tevogen

$5.90 -31% in 6 monthsMarket cap $405.2M

TVGN on XNAS, Health Care, Tevogen Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 71% in a year, with cash of just $145K against $1.7M of debt.

  • BadInstitutional holders fell to 24 from 31 last quarter
  • Bad4 director or officer changes filed in the last 90 days

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Tevogen Inc is a healthcare enterprise engaged in biotechnology, artificial intelligence and technology, and healthcare services. Its operations focus on the development of biotechnology products, AI- and technology-based healthcare solutions, and healthcare service initiatives.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
18
Website
tevogen.com
Listed
Nasdaq, US
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $7.0M.
Quarter to 31 Dec 2021: revenue –, net income -$17KQuarter to 31 Mar 2022: revenue –, net income -$26KQuarter to 30 Jun 2022: revenue –, net income $207KQuarter to 30 Sep 2022: revenue –, net income $1.6MQuarter to 31 Dec 2022: revenue –, net income $2.6MQuarter to 31 Mar 2023: revenue –, net income $1.2MQuarter to 30 Jun 2023: revenue –, net income -$195KQuarter to 30 Sep 2023: revenue –, net income -$279KQuarter to 31 Dec 2023: revenue –, net income -$829KQuarter to 31 Mar 2024: revenue –, net income $11.3MQuarter to 30 Jun 2024: revenue –, net income -$9.7MQuarter to 30 Sep 2024: revenue –, net income -$5.9MQuarter to 31 Mar 2025: revenue –, net income -$10.4MQuarter to 30 Jun 2025: revenue –, net income -$5.5MQuarter to 30 Sep 2025: revenue –, net income -$5.7MQuarter to 31 Dec 2025: revenue –, net income -$4.7MQuarter to 31 Mar 2026: revenue –, net income -$5.4MQuarter to 30 Jun 2026: revenue –, net income -$5.8MQuarter to 30 Sep 2026: revenue –, net income -$7.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $11.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$7.0M
30 Jun 2026–-$5.8M
31 Mar 2026–-$5.4M
31 Dec 2025–-$4.7M
30 Sep 2025–-$5.7M
30 Jun 2025–-$5.5M
31 Mar 2025–-$10.4M
30 Sep 2024–-$5.9M
30 Jun 2024–-$9.7M
31 Mar 2024–$11.3M
31 Dec 2023–-$829K
30 Sep 2023–-$279K
30 Jun 2023–-$195K
31 Mar 2023–$1.2M
31 Dec 2022–$2.6M
30 Sep 2022–$1.6M
30 Jun 2022–$207K
31 Mar 2022–-$26K
31 Dec 2021–-$17K
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$22.9M -$31.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $145K $1.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $1.7M $1.7M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $1.5M $614K
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
TevogenTVGN (this company) $405.2Mloss–––
Tectonic TherapeuticTECX $405.3Mloss–––
Candel TherapeuticsCADL $395.4Mloss–––
IRulya TherapeuticsIRLA $432.4Mloss–––
Fennec PharmaceuticalsFENC $462.1M2287.0+71%3.1%
AlectorALEC $347.6M8.42.0+151%23.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-23%

24 13F filers vs 31

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

0.1%

63K shares held by 13F filers (30 Sep 2026) of 68.7M outstanding (16 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.1%

55K shares sold short (30 Oct 2026) of 68.7M outstanding (16 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.3

55K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-1.0%

55K shares sold short in the report before, 55K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

13%

13% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

8 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $5.90 on 20 Nov 2026, -71% over 12 months (12-month range $3.89 to $24.05)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $7K in the last 12 months (the 12 months before: -$2.5M).
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 24 13F filers reported holding it in the latest 13F quarter, -52% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
4 Nov 20268-K and other filingsDirector or officer change
2 Nov 20268-K and other filingsDirector or officer change
16 Sep 20268-K and other filingsDirector or officer change
26 Aug 20268-K and other filingsDirector or officer change
26 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Apr 20268-K and other filingsDelisting notice or listing transfer
25 Feb 20268-K and other filingsDirector or officer change
25 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Sep 20258-K and other filingsDelisting notice or listing transfer
13 May 2025Sharp changeShort interest spike: short interest spike, 3.2M vs usual 1.0M (2025-04-30); 4.7x the same period a year earlier
1 Apr 20258-K and other filingsReport will be filed late
15 Nov 20248-K and other filingsReport will be filed late
23 Aug 20248-K and other filingsDirector or officer change
23 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Aug 20248-K and other filingsRegistered new securities for sale (S-1)
23 Jul 20248-K and other filingsRegistered new securities for sale (S-1)
21 Jun 20248-K and other filingsRegistered new securities for sale (S-1)
21 Jun 20248-K and other filingsDelisting notice or listing transfer
21 Jun 20248-K and other filingsA major agreement ended
16 May 20248-K and other filingsReport will be filed late
2 May 20248-K and other filingsChanged its auditor
2 Apr 20248-K and other filingsReport will be filed late
14 Feb 20248-K and other filingsDirector or officer change
14 Feb 20248-K and other filingsCompleted an acquisition or asset sale
14 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 20238-K and other filingsReport will be filed late
7 Jun 20238-K and other filingsDirector or officer change
7 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 May 20238-K and other filingsReport will be filed late
9 May 20238-K and other filingsDelisting notice or listing transfer
7 Apr 20238-K and other filingsDelisting notice or listing transfer
31 Mar 20238-K and other filingsReport will be filed late
29 Mar 20238-K and other filingsDelisting notice or listing transfer
16 May 20228-K and other filingsReport will be filed late
15 Apr 20228-K and other filingsDirector or officer change
15 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Apr 20228-K and other filingsReport will be filed late
Insider net buying (open market)
Month from 1 Jun 2023: -$9.0M published
Month from 1 Jul 2023: -$24.8M published
Month from 1 Jun 2024: $4K published
Month from 1 Oct 2024: -$1.7M published
Month from 1 Mar 2025: -$736K published
Month from 1 Jun 2025: -$1.8M published
Month from 1 Mar 2026: -$7K published
Capital spending per quarter
Quarter ended 31 Mar 2023: $133K; public on 29 May 2024
Quarter ended 30 Jun 2023: $0; public on 15 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 20 Nov 2024
Quarter ended 31 Dec 2023: $0; public on 3 Apr 2025
Institutional holders (13F filers)
31 Mar 2024 report: 5; public on 15 May 2024
30 Jun 2024 report: 27; public on 14 Aug 2024
30 Sep 2024 report: 34; public on 14 Nov 2024
31 Dec 2024 report: 42; public on 14 Feb 2025
31 Mar 2025 report: 50; public on 15 May 2025
30 Jun 2025 report: 52; public on 14 Aug 2025
30 Sep 2025 report: 50; public on 14 Nov 2025
31 Dec 2025 report: 49; public on 17 Feb 2026
31 Mar 2026 report: 30; public on 15 May 2026
30 Jun 2026 report: 31; public on 14 Aug 2026
30 Sep 2026 report: 24; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is cash from operations, fiscal year at -$12.3M (31 Dec 2025), 796% below its normal quarter of -$1.4M; higher than 25% of its own history.
  • Insider net buying (open market): Insiders sold a net $7K in the last 12 months (the 12 months before: -$2.5M).
  • Capital spending per quarter: Capital spending $0 in the latest quarter.
  • Institutional holders (13F filers): 24 13F filers reported holding it in the latest 13F quarter, -52% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 11 insider trades

No trades in the last 90 days; the latest was filed 17 Mar 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
17 Mar 2026Neal FlomenbergSee RemarksSell972$6.83$7KForm 4
9 Jun 2025Ryan H. SaadiChief Executive OfficerSell1,438,206$1.23$1.8MForm 4
14 Mar 2025Neal FlomenbergSee RemarksSell232,968$1.09$254KForm 4
11 Mar 2025Neal FlomenbergSee RemarksSell211,909$1.09$232KForm 4
6 Mar 2025Neal FlomenbergSee RemarksSell213,817$1.17$250KForm 4
18 Oct 2024Neal FlomenbergSee RemarksSell1,078,600$1.62$1.7MForm 4
13 Jun 2024Kirti DesaiChief Financial OfficerBuy3,000$0.82$2KForm 4
7 Jun 2024Ryan H. SaadiChief Executive OfficerBuy2,607$0.77$2KForm 4

24 institutions reported shares at the end of Q3 2026, 0% of the shares outstanding; 3 opened a position, 9 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Vanguard Capital Management LLC17K0.02%$112K-7,035-29%
Citadel Advisors LLC17K0.02%$111KNew+17K
Geode Capital Management, LLC12K0.02%$77KNew+12K
Vanguard Fiduciary Trust Co7,5150.01%$50K+6,677+797%
Morgan Stanley4,6950.01%$31K-14K-75%
Russell Investments Group, Ltd.3,8500.01%$25K-2,682-41%
FMR LLC (Fidelity)8310.00%$6K-8,995-92%
Royal Bank of Canada1540.00%$1KNo change
UBS Group AG1490.00%$986-934-86%
BNP Paribas Financial Markets1210.00%$801No change

Company events

All 49 company events

In 12 months: 5 director or officer changes, 1 delisting notice, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
4 Nov 2026Director or officer change8-K
2 Nov 2026Director or officer change; Signed a major agreementSame filing: took on new debt, sold shares privately8-K
16 Sep 2026Director or officer change8-K
26 Aug 2026Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
22 Apr 2026Delisting notice or listing transfer8-K
25 Feb 2026Director or officer changeSame filing: shareholder vote results8-K
26 Sep 2025Delisting notice or listing transfer8-K
3 Jul 2025Signed a major agreement8-K

Reported lobbying spend: $30K in Q2 2021, $30K in Q1 2021. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
24 Jul 2021EndedThe Livingston Group, LLCfor Tevogen BioH.R. 4502, S.____, FY 2022, Labor/HHS/Education Appropriations bill regarding HHS COVID-19 and virus variant vaccine funding.BudgetFiling
25 Jan 2021NewThe Livingston Group, LLCfor Tevogen BioCovid-19 countermeasuresBudgetFiling

The 5 newest of 34 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 4 Nov 2026Filings record

    Director or officer change

  2. 2 Nov 2026Filings record

    Director or officer change

  3. 16 Sep 2026Filings record

    Director or officer change

  4. 26 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 26 Aug 2026Filings record

    Director or officer change

  6. 22 Apr 2026Filings record

    Delisting notice or listing transfer

  7. 25 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 25 Feb 2026Filings record

    Director or officer change

  9. 26 Sep 2025Filings record

    Delisting notice or listing transfer

  10. 10 May 2025Short interest and volume change

    had 3.2M shares sold short in the 30 Apr 2025 report, 4.7× the same report last year.

    Same report last year: 681K; its normal report is 1.0M.

    See the evidence
    This period
    3.2M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    1.0M
    Typical spread (median absolute deviation)
    423K
    How far from its usual level
    +3.5
    Same report last year
    681K
    History used
    440 days
    2024-04-30: 681K2024-05-15: 906K2024-05-31: 191K2024-06-14: 153K2024-06-28: 207K2024-07-15: 541K2024-07-31: 504K2024-08-15: 649K2024-08-30: 595K2024-09-13: 690K2024-09-30: 579K2024-10-15: 3.2M2024-10-31: 3.7M2024-11-15: 775K2024-11-29: 1.5M2024-12-13: 1.2M2024-12-31: 1.1M2025-01-15: 1.2M2025-01-31: 2.8M2025-02-14: 1.5M2025-02-28: 1.3M2025-03-14: 1.4M2025-03-31: 1.3M2025-04-15: 1.5M2025-04-30: 3.2M
    the 30 Apr 2025 report24 earlier reportsnormal: 1.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 1 Apr 2025Filings record

    Report will be filed late

  12. 15 Nov 2024Filings record

    Report will be filed late

  13. 23 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 23 Aug 2024Filings record

    Director or officer change

  15. 1 Aug 2024Filings record

    Registered new securities for sale (S-1) (dated 31 Jul 2024)

  16. 23 Jul 2024Filings record

    Registered new securities for sale (S-1)

  17. 21 Jun 2024Filings record

    Registered new securities for sale (S-1)

  18. 21 Jun 2024Filings record

    Delisting notice or listing transfer

  19. 21 Jun 2024Filings record

    A major agreement ended

  20. 14 Jun 2024Insiders record

    Desai Kirti (Chief Financial Officer) bought 3,000 shares of TVGN ($2,460) (dated 13 Jun 2024)

  21. 8 Jun 2024Insiders record

    Saadi Ryan H. (Chief Executive Officer) bought 2,607 shares of TVGN ($2,008) (dated 7 Jun 2024)

  22. 16 May 2024Filings record

    Report will be filed late

  23. 2 May 2024Filings record

    Changed its auditor

  24. 2 Apr 2024Filings record

    Report will be filed late

  25. 14 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 14 Feb 2024Filings record

    Director or officer change

  27. 14 Feb 2024Filings record

    Completed an acquisition or asset sale

  28. 14 Aug 2023Filings record

    Report will be filed late

  29. 7 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 7 Jun 2023Filings record

    Director or officer change

  31. 15 May 2023Filings record

    Report will be filed late

  32. 9 May 2023Filings record

    Delisting notice or listing transfer

  33. 7 Apr 2023Filings record

    Delisting notice or listing transfer

  34. 31 Mar 2023Filings record

    Report will be filed late

  35. 29 Mar 2023Filings record

    Delisting notice or listing transfer

  36. 16 May 2022Filings record

    Report will be filed late

  37. 15 Apr 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 15 Apr 2022Filings record

    Director or officer change

  39. 1 Apr 2022Filings record

    Report will be filed late (dated 31 Mar 2022)

  40. 9 Nov 2021Insiders record

    Semper Paratus Sponsor LLC (ten percent owner) bought 1,300,000 shares of LGSTU] (dated 8 Nov 2021)

Showing the newest 40 of 50 entries; narrow the window or the kind of data to see older ones.

Not listed: 56 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001860871
Ticker
TVGN
Domain
tevogen.com
Hq location
NJ|WARREN|07059 (1 unverified)
Lobbying client
tevogen bio
Name
EX-21.1, ex21-1.htm, Semper Paratus Acquisition Corp, Tevogen Bio Holdings Inc. and 2 more
  • Federal lobbying disclosures (LDA)2 records, 8 data points25 Jan 2021 to 30 Sep 2021
  • SEC Form 13F institutional holdings99 data points31 Mar 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)84 records7 Oct 2021 to 16 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)227 data points20 Apr 2021 to 16 Nov 2026
  • SEC Form 4 insider transactions11 records, 44 data points8 Nov 2021 to 17 Mar 2026
  • FINRA short interest (twice monthly)198 data points15 Feb 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1388 data points15 Feb 2024 to 20 Nov 2026